India’s Ranbaxy faces more regulatory scrutiny after U.S. ban

By Sumeet Chatterjee MUMBAI (Reuters) – Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a U.S. ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs. India's biggest drugmaker by revenue, like rival Wockhardt Ltd, has had factories stopped from sending drugs and ingredients to its biggest market because the U.S. Food and Drug Administration (FDA) said the plants fell short of "good manufacturing practices".